» Articles » PMID: 32392235

Life Expectancy and Survival Analysis of Patients with Diabetes Compared to the Non Diabetic Population in Bulgaria

Abstract

Aims: To evaluate the expected life expectancy in patients with diabetes in Bulgaria and to compare it to the expected life expectancy of the non-diabetic population in the country.

Methods: It is a retrospective observational population study on individuals diagnosed with diabetes, compared to the non-diabetic population in Bulgaria for the period 2012-2015. Data from the national diabetes register and national statistical institute were used to construct life-tables with probability of survival with t-test and Chi Square test. Confounder analysis was done by age, sex, and type of diabetes. All-cause mortality and deaths in diabetic patients were analyzed. Kaplan-Meier survival curves were constructed for each age group and a log-rank analysis was conducted.

Results: Average life expectancy in the non-diabetic population, patients with Type 1 DM and with Type 2 DM is 74.8; 70.96 and 75.19 years, respectively. For 2012-2015 the mortality in the non-diabetic population remained constant and lower (average-1.48%) compared to type-1 DM (5.25%) and Type-2 (4.27%). Relative risk of death in diabetics was higher overall (12%), after the age of 70 before which the relative risk was higher for the non-diabetic population. This was observed as a trend in all analyzed years.

Conclusion: Patients with type 2 DM have a longer life-expectancy than patients with type-1 DM and overall Diabetics life expectancy equals that of the non-diabetic population, which could suggest improved disease control and its associated complications in Bulgaria. Male diabetics show slightly longer life expectancy than their counterparts in the non-diabetic population, by a marginal gain of 0.6 years for the entire observed period. Life expectancy in diabetic women increased by 1.3 years, which was not observed in the non-diabetic population. Prevalence of diabetes was higher for women. Improved diabetes control may explain this gain in life; however other studies are needed to confirm this.

Citing Articles

Antidiabetic Medicines Utilisation During Pre-Pandemic, Pandemic and Post-Pandemic Period of COVID-19-Data for Bulgarian Population.

Mitkova Z, Stanimirova D, Manova M, Gerasimov N, Mitov K, Petrova G Healthcare (Basel). 2025; 13(3).

PMID: 39942512 PMC: 11817434. DOI: 10.3390/healthcare13030322.


A systematic review and meta-analysis of the effect of hyperglycemia on admission for acute myocardial infarction in diabetic and non-diabetic patients.

Alawaji R, Musslem M, Alshalahi E, Alanzan A, Sufyani A, Alhati M Diabetol Metab Syndr. 2024; 16(1):224.

PMID: 39267155 PMC: 11391676. DOI: 10.1186/s13098-024-01459-w.


Relationship Between Frailty and Diabetic Pharmacologic Therapy in Older Adults with Type 2 Diabetes: A Cross-Sectional Study.

Nishimura A, Masuda C, Murauchi C, Ishii M, Murata Y, Kawasaki T Drugs Aging. 2024; 41(6):531-542.

PMID: 38795310 PMC: 11193829. DOI: 10.1007/s40266-024-01119-8.


Risk of diabetes and expected years in life without diabetes among adults from an urban community in India: findings from a retrospective cohort.

Sharma P, Dilip T, Kulkarni A, Mishra U, Shejul Y BMC Public Health. 2024; 24(1):1048.

PMID: 38622601 PMC: 11020643. DOI: 10.1186/s12889-024-18465-2.


Sirolimus-coated balloon in all-comer population of coronary artery disease patients: the EASTBOURNE DIABETES prospective registry.

Caiazzo G, Oliva A, Testa L, Heang T, Lee C, Milazzo D Cardiovasc Diabetol. 2024; 23(1):52.

PMID: 38310281 PMC: 10838457. DOI: 10.1186/s12933-024-02139-9.


References
1.
Bardenheier B, Lin J, Zhuo X, Ali M, Thompson T, Cheng Y . Disability-Free Life-Years Lost Among Adults Aged ≥50 Years With and Without Diabetes. Diabetes Care. 2016; 39(7):1222-9. PMC: 5884095. DOI: 10.2337/dc15-1095. View

2.
Roper N, Bilous R, Kelly W, Unwin N, Connolly V . Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ. 2001; 322(7299):1389-93. PMC: 32252. DOI: 10.1136/bmj.322.7299.1389. View

3.
Livingstone S, Levin D, Looker H, Lindsay R, Wild S, Joss N . Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015; 313(1):37-44. PMC: 4426486. DOI: 10.1001/jama.2014.16425. View

4.
Leal J, Gray A, Clarke P . Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J. 2008; 30(7):834-9. PMC: 2663724. DOI: 10.1093/eurheartj/ehn567. View

5.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View